A Prospective Trial of Intensity Modulated Radiation Therapy (IMRT) Incorporating a Simultaneous Integrated Boost for...

Area of Science:

• Radiation Oncology
• Medical Imaging
• Prostate Cancer Treatment

Background:

• Localized prostate cancer treatment traditionally relies on external beam radiation therapy.
• Integrating advanced imaging for dose escalation in prostate cancer remains an area of active research.
• Intensity Modulated Radiation Therapy (IMRT) allows for precise radiation delivery.

Purpose of the Study:

• To evaluate the long-term outcomes of intensity modulated radiation therapy (IMRT) for localized prostate cancer.
• To assess the efficacy of integrating a ¹¹¹In capromab pendetide (ProstaScint) scan-directed simultaneous integrated boost (SIB).
• To compare outcomes with and without the simultaneous integrated boost (SIB) in prostate cancer patients.

Main Methods:

• A prospective trial involving 71 patients with localized prostate cancer treated with IMRT.
• Coregistration of ProstaScint and pelvic CT scans for treatment planning.
• Prostate received 75.6 Gy (42 fractions); SIB to uptake regions received 82 Gy; adjuvant hormonal therapy based on risk stratification.

Main Results:

• 10-year biochemical control rates were 85% for the cohort receiving SIB, compared to 61% for historical controls without SIB (P=.02).
• 10-year survival rate for the SIB cohort was 69%.
• Higher pretreatment PSA (>10 ng/mL) and larger boost volumes (>10% prostate) correlated with poorer outcomes; SIB did not increase toxicity.

Conclusions:

• IMRT integrating ProstaScint scan-directed SIB is a feasible strategy for localized prostate cancer.
• The addition of SIB significantly improved long-term biochemical control without increasing toxicity.
• Modern imaging and dose escalation techniques offer favorable long-term disease control.